Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 7/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8235857 | 0.88 | GABRG2 (0.46) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL8238520 | 0.88 | GABRG2 (0.48) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL17088098 | 0.84 | GABRG2 (0.54) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL8229904 | 0.84 | GABRG2 (0.51) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL16638528 | 0.82 | GABRG2 (0.57) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL8235774 | 0.82 | GABRG2 (0.50) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL8422993 | 0.81 | GABRG2 (0.58) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL13693911 | 0.79 | GABRG2 (0.46) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL8235486 | 0.77 | GABRG2 (0.78) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL2851649 | 0.77 | GABRG2 (0.78) | GABRG2GABRB3GABRA5GABRA2GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130479-A1 | Gabaergic Agents to Treat Memory Deficits | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-27 | — | — | US | disclosed |
| US-20100130479-A1 | Gabaergic Agents to Treat Memory Deficits | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-27 | — | — | US | disclosed |
| US-7595395-B2 | Gabaergic agents to treat memory deficits | WISYS TECHNOLOGY FOUNDATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595395-B2 | Gabaergic agents to treat memory deficits | WISYS TECHNOLOGY FOUNDATION (US) | 2009-09-29 | — | — | US | disclosed |
| WO-2007018660-A2 | GABAERGIC IMIDAZOBENZODIAZEPINE DERIVATIVES TO TREAT MEMORY DEFICITS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20060258643-A1 | GABAERGIC AGENTS TO TREAT MEMORY DEFICITS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2006-11-16 | — | — | US | disclosed |
| US-20060258643-A1 | GABAERGIC AGENTS TO TREAT MEMORY DEFICITS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130479-A1 | Gabaergic Agents to Treat Memory Deficits | GABRA5, GABRA6, GABRB1 | GABRG2 15/4885GABRB3 6/4885GABRA5 1/4885 |
| US-20060258643-A1 | GABAERGIC AGENTS TO TREAT MEMORY DEFICITS | GABRA5, GABRA6, GABRA1 | GABRG2 16/4885GABRB3 10/4885GABRA5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.